中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(1): 33-46

Expert consensus on diagnosis and treatment of chronic hepatitis B with the integrated traditional Chinese and western medicine （2025）

DOI: 10.12449/JCH260106
Research funding:

National Administration of Traditional Chinese Medicine Key Discipline of Integrated Traditional Chinese and Western Medicine Clinical （Gastroenterology） (zyyzdxk-2023271);

The "Zhuoyuan" Project of the High-level Capacity Building Program of Dongfang Hospital, Beijing University of Chinese Medicine (DFRCZY-2024GJRC001);

The "Zhuoyuan" Project of the High-level Capacity Building Program of Dongfang Hospital, Beijing University of Chinese Medicine (DFRCZY-2024GJRC010);

National Famous Traditional Chinese Medicine Inheritance Studio （Letter of Personnel Education of the Office of Traditional Chinese Medicine of The State Council （2022）245） 

  • Received Date: 2025-12-15
  • Accepted Date: 2025-12-25
  • Published Date: 2026-01-25
    Abstract
  • Chronic hepatitis B is still one of the main chronic Iiver diseases in China. Although antiviral therapy has achieved good therapeutic effects， there are still many problems that have not been solved. To assist clinical physicians in accurately and reasonably diagnosing and treating chronic hepatitis B， this consensus elaborateson the understanding， diagnosis， and treatment of chronic hepatitis B from both perspectives of traditional Chinese and Western medicine， It comprehensively and deeply presents the Iatest research progress in this field， so as to provide a reference for clinical practice.

     

    • FullText(HTML)
  • loading
    • References(50)
  • [1]
    World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[R]. Geneva: WHO, 2024.
    [2]
    LI XR, JI ZR, WANG M, et al. Summary of chief physician Hao mingxia’s experience in“treating liver disease in four Chinese medicinal formulae”[J]. World J Integr Tradit West Med, 2023, 9( 3): 34- 45. DOI: 10.70976/j.2096-0964.2023.3.34-45.
    [3]
    World Health Organization. Global hepatitis report 2024:Action for access in low-and middle-income countries, 2024[R]. Geneva, Switzerland: 2024.
    [4]
    GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 796- 829. DOI: 10.1016/S2468-1253(22)00124-8.
    [5]
    ZHOU LL, BAI XX, DONG B, et al. Analysis of the clinical characteristics of HBeAg-negative chronic HBV infection in indeterminate phase with a low viral load[J]. Chin J Hepatol, 2024, 32( 11): 970- 975. DOI: 10.3760/cma.j.cn501113-20231028-00158.

    周路路, 白萧萧, 东冰, 等. 低病毒载量HBeAg阴性慢性HBV感染者不确定期临床特征分析[J]. 中华肝脏病杂志, 2024, 32( 11): 970- 975. DOI: 10.3760/cma.j.cn501113-20231028-00158.
    [6]
    LIU ZQ, LIN CQ, MAO XH, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: A systematic literature review and meta-analysis of 3740 studies and 231 million people[J]. Gut, 2023, 72( 12): 2354- 2363. DOI: 10.1136/gutjnl-2023-330691.
    [7]
    PARK JH, IWAMOTO M, YUN JH, et al. Structural insights into the HBV receptor and bile acid transporter NTCP[J]. Nature, 2022, 606( 7916): 1027- 1031. DOI: 10.1038/s41586-022-04857-0.
    [8]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for prevention and treatment of chronic hepatitis B(2010 edition)[J]. J Clin Hepatol, 2011, 27( 1): 113- 128.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 临床肝胆病杂志, 2011, 27( 1): 113- 128.
    [9]
    ASAMI J, KIMURA KT, FUJITA-FUJIHARU Y, et al. Structure of the bile acid transporter and HBV receptor NTCP[J]. Nature, 2022, 606( 7916): 1021- 1026. DOI: 10.1038/s41586-022-04845-4.
    [10]
    ZHUANG H. Attach importance to hepatitis D research[J]. J Clin Hepatol, 2023, 39( 4): 737- 741. DOI: 10.3969/j.issn.1001-5256.2023.04.001.

    庄辉. 重视丁型肝炎研究[J]. 临床肝胆病杂志, 2023, 39( 4): 737- 741. DOI: 10.3969/j.issn.1001-5256.2023.04.001.
    [11]
    Hepatobiliary Specialized Committee of China Association of Chinese Medicine, Liver Diseases Specialized Committee of China Medical Associa- tion of Minorities. The clinical guidelines of diagnosis and treatment of chronic hepatitis B with traditional Chinese medicine(2018)[J]. J Clin Hepatol, 2018, 34( 12): 2520- 2525. DOI: 10.3969/j.issn.1001-5256.2018.12.007.

    中华中医药学会肝胆病专业委员会, 中国民族医药学会肝病专业委员会. 慢性乙型肝炎中医诊疗指南(2018年版)[J]. 临床肝胆病杂志, 2018, 34( 12): 2520- 2525. DOI: 10.3969/j.issn.1001-5256.2018.12.007.
    [12]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update[J]. Chin J Hepatol, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [13]
    HOU JL, ZHAO W, LEE C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol, 2020, 18( 2): 457- 467. e 21. DOI: 10.1016/j.cgh.2019.07.010.
    [14]
    WEN ZJ. Enhancing the understanding of the risk of incident fracture in entecavir- and TDF-treated elderly patients with chronic hepatitis B[J]. J Hepatol, 2024, 81( 4): e198. DOI: 10.1016/j.jhep.2024.05.012.
    [15]
    AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68( 4): 672- 681. DOI: 10.1016/j.jhep.2017.11.039.
    [16]
    BYUN KS, CHOI J, KIM JH, et al. Tenofovir alafenamide for drug-resistant hepatitis B: A randomized trial for switching from tenofovir disoproxil fumarate[J]. Clin Gastroenterol Hepatol, 2022, 20( 2): 427- 437.e5. DOI: 10.1016/j.cgh.2021.04.045.
    [17]
    OGAWA E, NAKAMUTA M, KOYANAGI T, et al. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: Week 144 results from a real-world, multi-centre cohort study[J]. Aliment Pharmacol Ther, 2022, 56( 4): 713- 722. DOI: 10.1111/apt.17107.
    [18]
    WU D, WANG P, HAN MF, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: The endeavor study[J]. Hepatol Int, 2019, 13( 5): 573- 586. DOI: 10.1007/s12072-019-09956-1.
    [19]
    LIU ZH, JIN QL, ZHANG YX, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54( 9): 1134- 1149. DOI: 10.1111/apt.16611.
    [20]
    HAN MF, JIANG JJ, HOU JL, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study[J]. Antivir Ther, 2016, 21( 4): 337- 344. DOI: 10.3851/IMP3019.
    [21]
    HU P, SHANG J, ZHANG WH, et al. HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New switch study[J]. J Clin Transl Hepatol, 2018, 6( 1): 25- 34. DOI: 10.14218/JCTH.2017.00072.
    [22]
    SONG CY, CHEN JJ, LING QH, et al. The observation of clinical effect of combined treatment of combined artemisiae capillariae decoction and entecavir on HBeAg positive chronic hepatitis B with damp-heat in liver and gallbladder for seven years[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 7): 588- 591. DOI: 10.3969/j.issn.1005-0264.2023.007.003.

    宋尘悦, 陈建杰, 凌琪华, 等. 茵陈蒿汤加味联合恩替卡韦治疗肝胆湿热证HBeAg阳性慢性乙型肝炎7年疗效分析[J]. 中西医结合肝病杂志, 2023, 33( 7): 588- 591. DOI: 10.3969/j.issn.1005-0264.2023.007.003.
    [23]
    WU QL. Clinical analysis of modified Ganlu Disinfection pills in the treatment of chronic Hepatitis B[J]. Shenzhen J Integr Tradit Chin West Med, 2015, 25( 4): 67- 68. DOI: 10.16458/j.cnki.1007-0893.2015.04.040

    吴巧灵. 甘露消毒丹加减治疗慢性乙型肝炎的临床分析[J]. 深圳中西医结合杂志, 2015, 25( 4): 67- 68. DOI: 10.16458/j.cnki.1007-0893.2015.04.040
    [24]
    ZHAO CQ, CAI H, CHEN GF, et al. The effect of Qingre Huashi formula on chronic hepatitis B or nonalcoholic fatty liver disease with damp-heat syndrome: A multicenter randomized double-blind placebo-controlled Trial[J]. J Tradit Chin Med, 2022, 63( 8): 745- 753. DOI: 10.13288/j.11-2166/r.2022.08.010.

    赵超群, 蔡虹, 陈高峰, 等. 清热化湿方治疗慢性乙型肝炎及非酒精性脂肪性肝病湿热证的多中心随机双盲安慰剂对照试验[J]. 中医杂志, 2022, 63( 8): 745- 753. DOI: 10.13288/j.11-2166/r.2022.08.010.
    [25]
    ZHANG GD, HUAN J, ZHU YB, et al. Effect of Dangfei Liganning capsule combined with interferon on serum levels of SII, NLR, PLR and MLR in patients with chronic hepatitis B liver fibrosis[J]. Chin Arch Tradit Chin Med, 2022, 40( 4): 183- 186. DOI: 10.13193/j.issn.1673-7717.2022.04.041.

    张国栋, 郇娟, 朱英斌, 等. 当飞利肝宁胶囊联合干扰素对慢性乙型肝炎肝纤维化血清SII、NLR、PLR、MLR水平的影响[J]. 中华中医药学刊, 2022, 40( 4): 183- 186. DOI: 10.13193/j.issn.1673-7717.2022.04.041.
    [26]
    ZHONG R, DUAN ZP, CHEN Y, et al. Clinical study of Pien Tze Huang in treatment of chronic hepatitis B[J]. Chin J Gastroenterol Hepatol, 2017, 26( 11): 1290- 1293. DOI: 10.3969/j.issn.1006-5709.2017.11.023.

    钟蕊, 段钟平, 陈煜, 等. 片仔癀治疗慢性乙型肝炎的临床研究[J]. 胃肠病学和肝病学杂志, 2017, 26( 11): 1290- 1293. DOI: 10.3969/j.issn.1006-5709.2017.11.023.
    [27]
    ZHANG X, ZHANG LW, JI LS, et al. Pien Tze Huang plus entecavir improves hepatic fibrosis in Chinese patients with chronic hepatitis B[J]. Phytomedicine, 2025, 142: 156741. DOI: 10.1016/j.phymed.2025.156741.
    [28]
    LI N, WANG LY, GUO YP, et al. Clinical effects of and influence on quality of life of Luohuazizhu particles on patients with chronic hepatitis B[J/CD]. Elect J Clin Med Literat, 2018, 5( 19): 28- 32.

    李娜, 王云丽, 郭亚平, 等. 裸花紫珠颗粒治疗慢性乙型肝炎疗效及对生活质量影响[J/CD]. 临床医药文献电子杂志, 2018, 5( 19): 28- 32.
    [29]
    YU LN, WANG ZY, ZI CX, et al. Efficacy and safety of modified Xiaoyao Powder against chronic hepatitis B:A Meta-analysis[J]. Chin Tradit Herb Drugs, 2022, 53( 24): 7831- 7842. DOI: 10.7501/j.issn.0253-2670.2022.24.020.

    余璐妮, 王梓怡, 字晨霞, 等. 逍遥散加减方治疗慢性乙型肝炎临床疗效及安全性Meta分析[J]. 中草药, 2022, 53( 24): 7831- 7842. DOI: 10.7501/j.issn.0253-2670.2022.24.020.
    [30]
    LI XK, ZHOU DQ, CHI XL, et al. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: A randomized, controlled trial[J]. Hepatol Int, 2020, 14( 6): 985- 996. DOI: 10.1007/s12072-020-10097-z.
    [31]
    ZHANG WY, ZHENG QN, ZHENG QX. Observation on curative effect of Wuling capsules combined with tenofovir for chronic hepatitis B with liver depression and spleen deficiency syndrome and its effect on liver fibrosis[J]. J New Chin Med, 2023, 55( 6): 42- 45. DOI: 10.13457/j.cnki.jncm.2023.06.009.

    张文奕, 郑琼娜, 郑秋霞. 五灵胶囊联合替诺福韦酯治疗肝郁脾虚证慢性乙型肝炎疗效观察及对肝纤维化的影响[J]. 新中医, 2023, 55( 6): 42- 45. DOI: 10.13457/j.cnki.jncm.2023.06.009.
    [32]
    JIN KJ, SHI SM, TONG C/Z)X. The efficacy of Ganshuang Granules combined with tenofovir disoproxil fumarate tablets in the treatment of chronic hepatitis B cirrhosis and its influence on liver fibrosis[J]. Chin J Clin Ration Drug Use, 2023, 16( 36): 74- 77. DOI: 10.15887/j.cnki.13-1389/r.2023.36.021.

    靳克俭, 史拴梅, 同重湘. 肝爽颗粒联合富马酸替诺福韦二吡呋酯片治疗慢性乙型肝炎肝硬化的疗效及对肝纤维化的影响[J]. 临床合理用药, 2023, 16( 36): 74- 77. DOI: 10.15887/j.cnki.13-1389/r.2023.36.021.
    [33]
    JI XL, CHANG F, JIN F, et al. Clinical study of Jiuwei Gantai capsule combined with entecavir on 42 cases of chronic hepatitis B[J]. Chin J Integr Tradit West Med Liver Dis, 2013, 23( 4): 203- 205. DOI: 10.3969/j.issn.1005-0264.2013.04.004.

    季雪良, 常峰, 金凤, 等. 九味肝泰胶囊联合恩替卡韦治疗慢性乙型肝炎临床研究[J]. 中西医结合肝病杂志, 2013, 23( 4): 203- 205. DOI: 10.3969/j.issn.1005-0264.2013.04.004.
    [34]
    ZHANG ZC, LU BJ. Observation on the therapeutic effect of Yiguanjian combined with entecavir in the treatment of chronic hepatitis B[J]. Yunnan J Tradit Chin Med Mater Med, 2022, 43( 11): 44- 47. DOI: 10.3969/j.issn.1007-2349.2022.11.011.

    张志城, 卢秉久. 一贯煎联合恩替卡韦治疗慢性乙型肝炎疗效观察[J]. 云南中医中药杂志, 2022, 43( 11): 44- 47. DOI: 10.3969/j.issn.1007-2349.2022.11.011.
    [35]
    DUAN SH, BAO ZY, YUAN XD, et al. Efficacy observation of Yiguanjian decoction combined adefovir dipivoxil tablet in treating HBeAg negative chronic viral hepatitis B active compensated liver cirrhosis patients[J]. Chin J Integr Tradit West Med, 2016, 36( 5): 535- 538. DOI: 10.7661/CJIM.2016.05.0535

    段淑红, 鲍中英, 苑晓冬, 等. 一贯煎加味联合阿德福韦酯片治疗HBeAg阴性慢性乙型肝炎活动性代偿期肝硬化患者的疗效观察[J]. 中国中西医结合杂志, 2016, 36( 5): 535- 538. DOI: 10.7661/CJIM.2016.05.0535
    [36]
    NIU CH, TIAN XQ, ZHU ZY. Analysis of the effect of Zishen Qinggan formula on patients with chronic hepatitis B syndrome of liver and kidney yin deficiency[J]. Pharmacol Clin Chin Mater Med, 2017, 33( 4): 160- 163.

    牛春红, 田新强, 朱壮彦. 滋肾清肝方对肝肾阴虚证型慢性乙型肝炎患者的效果分析[J]. 中药药理与临床, 2017, 33( 4): 160- 163.
    [37]
    ZHOU YF, LIU HY, FANG JX, et al. Meta-analysis of Liuwei Wuling tablets combined with entecavir in the treatment of chronic hepatitis B[J]. China Pharm, 2017, 28( 36): 5111- 5115. DOI: 10.6039/j.issn.1001-0408.2017.36.19.

    周永峰, 刘红宇, 房吉祥, 等. 六味五灵片联合恩替卡韦治疗慢性乙型肝炎的Meta分析[J]. 中国药房, 2017, 28( 36): 5111- 5115. DOI: 10.6039/j.issn.1001-0408.2017.36.19.
    [38]
    ZHANG FL, WU HF, WANG J, et al. Meta-analysis of Liuwei Wuling tablet combined with entecavir in the treatment of chronic hepatitis B cirrhosis[J]. Pharm Clin Chin Mater Med, 2020, 11( 6): 44- 53.

    章方玲, 吴和霏, 王建, 等. 六味五灵片联合恩替卡韦治疗慢性乙型肝炎肝硬化的Meta分析[J]. 中药与临床, 2020, 11( 6): 44- 53.
    [39]
    ZHONG ZK, ZHOU XL, ZHANG ZJ, et al. Clinical observation on the treatment of chronic hepatitis B liver fibrosis by acupoint injection of Jisheng Shenqi Decoction plus Sanqi and Bionychia combined with Dan-shen Injection[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 3): 242- 246. DOI: 10.3969/j.issn.1005-0264.2023.003.013.

    钟镇康, 周晓玲, 张志杰, 等. 加味济生肾气汤联合穴位注射丹参注射液治疗慢性乙型肝炎肝纤维化患者的临床观察[J]. 中西医结合肝病杂志, 2023, 33( 3): 242- 246. DOI: 10.3969/j.issn.1005-0264.2023.003.013.
    [40]
    ZHOU ZH, SUN XH, ZHU XJ, et al. The clinical research of Bushenjianpi formulae combined entecavir in treating hepatitis HBeAg positive chronic hepatitis B[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 7): 590- 592. DOI: 10.3969/j.issn.1005-0264.2021.07.004.

    周振华, 孙学华, 朱晓骏, 等. 补肾健脾方联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者的临床研究[J]. 中西医结合肝病杂志, 2021, 31( 7): 590- 592. DOI: 10.3969/j.issn.1005-0264.2021.07.004.
    [41]
    ZHANG JH, ZHANG X, ZHOU ZH, et al. Bushen Jianpi formula combined with entecavir for the treatment of HBeAg-negative chronic hepatitis B: A multicenter, randomized, double-blind, placebo-controlled trial[J]. Evid Based Complement Alternat Med, 2022, 2022: 6097221. DOI: 10.1155/2022/6097221.
    [42]
    HE XQ, HU GX. Meta-analysis of clinical effect of Gexia Zhuyu decoction on hepatitis B cirrhosis[J]. Shaanxi J Tradit Chin Med, 2021, 42( 3): 398- 401, 408. DOI: 10.3969/j.issn.1000-7369.2021.03.034.

    何湘琴, 胡国信. 膈下逐瘀汤治疗乙型肝炎肝硬化临床疗效Meta分析[J]. 陕西中医, 2021, 42( 3): 398- 401, 408. DOI: 10.3969/j.issn.1000-7369.2021.03.034.
    [43]
    BIAN Q, XIE XK, KOU XN, et al. Clinical study of Ruangan Huayu decoction combined with entecavir dispersible tablets in treating hepatitis B compensatory cirrhosis with blood stasis syndrome[J]. Chin J Inf Tradit Chin Med, 2021, 28( 3): 94- 99. DOI: 10.19879/j.cnki.1005-5304.202001120.

    边倩, 解新科, 寇小妮, 等. 软肝化瘀饮辅助恩替卡韦分散片治疗慢性乙型肝炎肝硬化代偿期瘀血阻络证临床研究[J]. 中国中医药信息杂志, 2021, 28( 3): 94- 99. DOI: 10.19879/j.cnki.1005-5304.202001120.
    [44]
    MENG XB, PAN ZQ, ZHAO JW, et al. Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis[J]. Medicine, 2022, 101( 46): e31664. DOI: 10.1097/MD.0000000000031664.
    [45]
    YANG QF, YE T, LIN ZC. Effect of Biejia Jian pills combined with entecavir on liver fibrosis indices in patients with chronic hepatitis B liver fibrosis: A systematic evaluation[J]. J Guangzhou Univ Tradit Chin Med, 2023, 40( 11): 2921- 2930. DOI: 10.13359/j.cnki.gzxbtcm.2023.11.036.

    杨乾方, 叶婷, 林子程. 鳖甲煎丸联合恩替卡韦对慢性乙型肝炎肝纤维化患者的肝纤维化指标影响的系统评价[J]. 广州中医药大学学报, 2023, 40( 11): 2921- 2930. DOI: 10.13359/j.cnki.gzxbtcm.2023.11.036.
    [46]
    ZHANG JL, YING HE, ZHANG X, et al. Fuzheng Huayu preparation(/) combined with tenofovir disoproxil fumarate on hepatitis B: A systematic review and Meta-analysis[J]. J Tradit Chin Med, 2023, 43( 2): 221- 230. DOI: 10.19852/j.cnki.jtcm.20221108.005.
    [47]
    CAI M, LIU N, PAN Y, et al. Meta-analysis of Anluo Huaxian Pills combined with entecavir in the treatment of liver fibrosis in chronic hepatitis B[J]. Mod J Integr Tradit Chin West Med, 2017, 26( 30): 3341- 3345.

    蔡敏, 刘娜, 潘玉, 等. 安络化纤丸联合恩替卡韦治疗慢性乙型肝炎肝纤维化的Meta分析[J]. 现代中西医结合杂志, 2017, 26( 30): 3341- 3345.
    [48]
    YANG XR, LIN L, WU HC, et al. Clinical observation on the treatment of damp-heat internal accumulation type chronic hepatitis B with traditional Chinese medicine acupoint application combined with peginterferon α-2b[J]. Tradit Chin Med J, 2022( 1): 42- 45.

    杨小荣, 林立, 吴昦辰, 等. 中药穴位贴敷联合聚乙二醇干扰素α-2b治疗湿热内结型慢性乙型肝炎临床观察[J]. 中医药通报, 2022, 21( 1): 42- 45.
    [49]
    LIU SH, ZHU XQ, JIN RJ, et al. Clinical study on moxibustion combined with entecavir for chronic hepatitis B of spleen-kidney Yang deficiency type[J]. J New Chin Med, 2023, 55( 14): 151- 155. DOI: 10.13457/j.cnki.jncm.2023.14.030.

    刘三海, 朱小区, 金若珏, 等. 艾灸联合恩替卡韦治疗脾肾阳虚型慢性乙型肝炎临床研究[J]. 新中医, 2023, 55( 14): 151- 155. DOI: 10.13457/j.cnki.jncm.2023.14.030.
    [50]
    CAI Y. Chronic hepatitis B in Chinese medicine iontophoresis combined with conventional treatment of liver stagnation and spleen deficiency type randomized controlled study[J]. J Pract Tradit Chin Intern Med, 2015, 29( 5): 170- 172. DOI: 10.13729/j.issn.1671-7813.2015.05.81

    蔡艳. 中药离子导入联合常规治疗肝郁脾虚慢性乙型病毒性肝炎随机平行对照研究[J]. 实用中医内科杂志, 2015, 29( 5): 170- 172. DOI: 10.13729/j.issn.1671-7813.2015.05.81
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (185) PDF downloads(90) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return